Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial

Publication | Closed Access

DOI

192

Citations

References

2018

Year

Jean‐Michel Molina, Douglas Ward, Indira Brar, Anthony Mills, Hans‐Jürgen Stellbrink, Luís F. López‐Cortés, Peter Ruane, Daniel Podzamczer, Cynthia Brinson, Joseph M. Custodio,

The Lancet HIV

Treatment And PreventionAntiviral Drug DevelopmentClinical TrialsAntiviral TherapyVirologyPharmacotherapyNon-inferiority TrialTenofovir AlafenamideHivAntiviral DrugMedicineAids PathogenesisWeek Results